Nicholas Butowski

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:175-82. 2009
  2. doi request reprint A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields
    Nicholas Butowski
    Associate Professor, UCSF Neurological Surgery, San Francisco, CA Electronic address
    Semin Oncol 40:S2-4. 2013
  3. doi request reprint Endpoints for clinical trials and revised assessment in neuro-oncology
    Nicholas Butowski
    Division of Neuro Oncology, Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143 0350, USA
    Curr Opin Neurol 25:780-5. 2012
  4. pmc Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 13:1331-8. 2011
  5. doi request reprint Anti-angiogenic therapy in glioma
    Nicholas Butowski
    Department of Neuro Oncology, Brain Tumor Research Center, University of California, San Francisco, CA 94143 0350, USA
    Clin Transl Oncol 13:294-300. 2011
  6. doi request reprint Medical management of brain metastases
    Nicholas Butowski
    Department of Neurological Surgery, University of California, 400 Parnassus Avenue 0372, San Francisco, CA 94143, USA
    Neurosurg Clin N Am 22:27-36, v-vi. 2011
  7. pmc Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 12:608-13. 2010
  8. doi request reprint Immunostimulants for malignant gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143, USA
    Neurosurg Clin N Am 21:53-65. 2010
  9. pmc A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:183-9. 2009
  10. ncbi request reprint Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    J Neurooncol 85:87-94. 2007

Detail Information

Publications26

  1. doi request reprint A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:175-82. 2009
    ....
  2. doi request reprint A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields
    Nicholas Butowski
    Associate Professor, UCSF Neurological Surgery, San Francisco, CA Electronic address
    Semin Oncol 40:S2-4. 2013
    ....
  3. doi request reprint Endpoints for clinical trials and revised assessment in neuro-oncology
    Nicholas Butowski
    Division of Neuro Oncology, Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94143 0350, USA
    Curr Opin Neurol 25:780-5. 2012
    ..However, inadequacies of clinical trial endpoints have challenged how best to evaluate promising new therapeutics...
  4. pmc Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 13:1331-8. 2011
    ..Adjusting for age and KPS, no other biomarker was associated with survival outcome. Correlation of relevant biomarkers with OS may be useful in future trials...
  5. doi request reprint Anti-angiogenic therapy in glioma
    Nicholas Butowski
    Department of Neuro Oncology, Brain Tumor Research Center, University of California, San Francisco, CA 94143 0350, USA
    Clin Transl Oncol 13:294-300. 2011
    ..This manuscript reviews the landscape of anti-angiogenic therapy in glioma, with a focus on GBM, and demonstrates that further innovation is needed to determine the true utility of anti-angiogenic therapy...
  6. doi request reprint Medical management of brain metastases
    Nicholas Butowski
    Department of Neurological Surgery, University of California, 400 Parnassus Avenue 0372, San Francisco, CA 94143, USA
    Neurosurg Clin N Am 22:27-36, v-vi. 2011
    ..Radiation therapy and surgery are discussed in detail elsewhere; however, a brief discussion of all of these modalities is included for the sake of thoroughness...
  7. pmc Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 12:608-13. 2010
    ..The proceeding phase II trial has finished accrual and results will be reported in 2009...
  8. doi request reprint Immunostimulants for malignant gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143, USA
    Neurosurg Clin N Am 21:53-65. 2010
    ..Combining these strategies with more than one mode of immunotherapy may provide better clinical results...
  9. pmc A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:183-9. 2009
    ..Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide...
  10. ncbi request reprint Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    J Neurooncol 85:87-94. 2007
    ..Patients treated during surgically based phase II studies should be matched with a historical control group restricted to patients with similar pretreatment variables, including GTR...
  11. pmc Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
    ..The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response...
  12. pmc Quality of life in low-grade glioma patients receiving temozolomide
    Raymond Liu
    Department of Medicine, Division of Hematology Oncology Neuro Oncology, University of California, San Francisco, CA 94143 2167, USA
    Neuro Oncol 11:59-68. 2009
    ..While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working...
  13. ncbi request reprint A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 61:1454-9. 2005
    ....
  14. pmc Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme
    Janine M Lupo
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158
    Neuro Oncol 15:480-9. 2013
    ....
  15. pmc Identifying the needs of brain tumor patients and their caregivers
    Rupa Parvataneni
    Division of Neuro Oncology in the Department of Neurosurgery, University of California, San Francisco, CA 94143, USA
    J Neurooncol 104:737-44. 2011
    ....
  16. pmc Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, CA 94143 0372, USA
    Neuro Oncol 8:67-78. 2006
    ..There was a modest pharmacokinetic interaction between erlotinib and temozolomide. The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted...
  17. pmc Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
    ..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era...
  18. doi request reprint Preoperative prognostic classification system for hemispheric low-grade gliomas in adults
    Edward F Chang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143, USA
    J Neurosurg 109:817-24. 2008
    ..As a result, the objective in the present study was to design a preoperative scoring system to prognosticate long-term outcomes in patients with LGGs...
  19. pmc Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
    Pin Yuan Chen
    Department of Neurological Surgery, University of California San Francisco, 1450 Third Street, Room HD 283, San Francisco, CA 94158, USA
    Neuro Oncol 15:189-97. 2013
    ....
  20. doi request reprint Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy
    Ashley H Aiken
    Department of Radiology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 72:1340-6. 2008
    ..To compare temporal patterns of recurrent contrast enhancement in patients with glioblastoma multiforme (GBM) treated with brachytherapy plus external beam radiotherapy (EBRT) vs. EBRT alone...
  21. doi request reprint Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
    ....
  22. doi request reprint Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein
    Courtney A Crane
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94141, USA
    Clin Cancer Res 19:205-14. 2013
    ..Here we show that peptides bound to a 96 kD chaperone protein (HSP-96) from brain tissue containing glioblastoma multiforme (GBM) can be used to safely immunize patients with recurrent GBM...
  23. pmc Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma
    Susan M Chang
    Department of Neurological Surgery, UCSF, 505 Parnassus Ave, San Francisco, CA 94143, USA
    J Neurooncol 92:401-15. 2009
    ....
  24. ncbi request reprint Small molecule and monoclonal antibody therapies in neurooncology
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, CA 94143 0350, USA
    Cancer Control 12:116-24. 2005
    ..These advances are being translated into new therapies that will hopefully improve the prognosis for patients with brain tumors...
  25. pmc GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 7:425-34. 2005
    ..Our guidelines are summarized in a checklist format that can be used as a framework from which to construct a phase 1 or 2 clinical trial...
  26. ncbi request reprint Therapeutic advances for glioblastoma multiforme: current status and future prospects
    H Ian Robins
    University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
    Curr Oncol Rep 9:66-70. 2007
    ..We anticipate that a multimodality approach directed at tumor-specific biology will result in more meaningful advancements in the treatment of this fatal disease...